


Brilliant Violet 421™ anti-mouse CD273 (B7-DC, PD-L2)

Catalog # / Size: 1136095 / 50 µg
Clone: TY25
Isotype: Rat IgG2a, κ
Immunogen: Mouse B7-DC transfected cell line
Reactivity: Mouse
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Concentration: 0.2 mg/ml



Mouse B7-DC transfected BHK cells were stained with CD273 (clone TY25) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).

Applications:

Applications: Flow Cytometry
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: Additional reported applications (for the relevant formats) include: immunoprecipitation¹, Western blotting^{1,6}, blocking^{2,4,5} of PD-1 mediated interactions, and immunohistochemistry of acetone-fixed frozen sections³.

Application References:
1. Shin T, *et al.* 2003. *J. Exp. Med.* 198:31.
2. Liu X, *et al.* 2003. *J. Exp. Med.* 197:1721.
3. Carreno BM, *et al.* 2002. *Annu. Rev. Immunol.* 20:29.

Description: B7-DC is also called programmed death ligand 2 (PDL2). It has recently been clustered as CD273. This ligand is a 42 kD member of the immunoglobulin receptor superfamily expressed on a subset of dendritic cells, liver and a small subset of macrophages as well as a few transformed cell lines. CD273 has been

reported to be stimulatory on dendritic cells when cross-linked and to inhibit T cell activation upon engaging the PD-1 receptor. CD273 has also been reported to bind to an alternative receptor and to mediate T cell activation through such non-PD1 mediated interactions. The TY25 antibody has been reported to be useful for blocking PD-1 mediated interactions.

Antigen
References:

1. Shin T, *et al.* 2003. *J. Exp. Med.* 198:31.
2. Liu X, *et al.* 2003. *J. Exp. Med.* 197:1721.
3. Carreno BM, *et al.* 2002. *Annu. Rev. Immunol.* 20:29.